We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is This the Right Time to Add PAHC Stock to Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Phibro Animal Health is driven by strong Animal Health growth, with MFA revenues up 34% in fiscal Q2.
PAHC's vaccine sales rose 13%, fueled by poultry demand in Latin America and global capacity expansion.
Phibro faces risks from macro pressures, trade disruptions and rising competition from generic products.
Phibro Animal Health Corporation (PAHC - Free Report) is well-poised to grow in the coming quarters, thanks to its ongoing momentum in the Animal Health business, supported by a stronger MFA (medicated feed additives) portfolio. The vaccine business is thriving on sustained global demand and capacity expansion. Phibro’s presence in high-growth regions outside the United States provides significant room to tap into global growth prospects. Meanwhile, headwinds from macroeconomic pressures and the growing use of generic products may hurt the company’s results.
Over the past year, this Zacks Rank #2 (Buy) stock has surged 251.1% against the industry’s 15% fall and the S&P 500 composite’s 34.5% growth.
The renowned animal health and mineral nutrition company has a market capitalization of $2.42 billion. PAHC has an earnings yield of 5.1% compared with the industry’s yield of 2.3%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.2%.
Let’s delve deeper.
Factors Favoring PAHC Stock
Robust Animal Health Growth: Within this, Phibro’s MFA portfolio was bolstered by the integration of Zoetis’ MFA business, which added more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China. In the second quarter of fiscal 2026, MFA revenues grew 34%, supported by strong gains in nutritional specialties and vaccines. The new MFA business contributed a full quarter of sales of $94.1 million compared with a partial quarter last year. Nutritional Specialty net sales increased 9% due to higher demand for dairy in North America.
Image Source: Zacks Investment Research
In October, the company signed a licensing agreement with Lighthouse Pharmaceuticals, Inc, gaining exclusive rights to develop, manufacture and commercialize the latter’s proprietary compound for canine periodontal care. Phibro also rolled out the Restoris piezoelectric dental gel nationwide, a product designed to treat and support long-term oral health in dogs with periodontal disease.
Vaccine Business Thrives: Phibro is focusing on new developments, along with incremental registrations and growing volumes of existing vaccine technologies. The company markets approximately 50 product lines for the prevention of diseases in poultry, including vaccines to protect against Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza. Phibro makes significant investments to expand vaccine manufacturing capacity at several locations, such as its vaccine production facility in Guarulhos, Brazil.
In the second quarter of fiscal 2026, net sales of vaccines increased 13% year over year, primarily driven by continued growth of poultry products in Latin America and higher international demand. Supported by expanding capacity and sustained global demand, the vaccines business is expected to emerge as a key growth driver in fiscal 2026.
Growth Potential in Emerging Markets: Phibro’s existing operations and established sales, marketing and distribution network in approximately 90 countries provide it ample scope to take advantage of global growth opportunities. Outside the United States, Phibro’s global footprint extends to key high-growth regions (countries where the livestock production growth rate is expected to be higher than the average growth rate), including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries, and South Africa and other countries in Africa. In the second quarter of fiscal 2026, net sales in Europe, the Middle East and Africa increased 37.4%, and Asia Pacific sales rallied 1.1%.
What Ails Phibro?
Macroeconomic Risks Loom: In the current scenario, Phibro’s business continues to be affected by economic sanctions, bans and broader military conflicts resulting from the ongoing armed conflict between Russia and Ukraine. Changes in the U.S. trade policy, including tariffs and revised trade agreements, could create supply-chain inefficiencies and affect the cost and availability of key materials. Other risks include macroeconomic instability from the exclusion of Russian financial institutions from the global banking system, inflationary pressures on raw materials and energy and heightened cybersecurity threats. All of these factors could reduce Phibro’s profitability and weigh on its overall financial performance.
Generic Pressure May Affect Growth: Phibro faces competition from lower-priced generic alternatives and new competitive products, limiting the protection afforded by its trade secrets. Generic competitors are becoming more aggressive in terms of pricing, and generic products form a considerable proportion of overall animal health sales in certain regions. If animal health customers increase their use of new or existing generic products, it will adversely affect Phibro’s financial health and operational performance.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2026 earnings per share (EPS) projects 45% growth to $3.03. The estimate has remained constant in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.48 billion. This suggests a 14.5% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Cardinal Health (CAH - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s negative 2.2% yield. Its earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 33.4% compared with the industry’s 4.7% growth in the past year.
BrightSpring Health Services, sporting a Zacks Rank #1 at present, has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. Shares of the company have surged 173.9% compared with the industry’s 0.7% growth in the past year. BTSG’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 40.4%.
Cardinal Health, carrying a Zacks Rank #2 (Buy), has an earnings yield of 4.8% compared with the industry’s 6.5% yield. Shares of the company have rallied 60% compared with the industry’s 12.7% growth. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is This the Right Time to Add PAHC Stock to Your Portfolio?
Key Takeaways
Phibro Animal Health Corporation (PAHC - Free Report) is well-poised to grow in the coming quarters, thanks to its ongoing momentum in the Animal Health business, supported by a stronger MFA (medicated feed additives) portfolio. The vaccine business is thriving on sustained global demand and capacity expansion. Phibro’s presence in high-growth regions outside the United States provides significant room to tap into global growth prospects. Meanwhile, headwinds from macroeconomic pressures and the growing use of generic products may hurt the company’s results.
Over the past year, this Zacks Rank #2 (Buy) stock has surged 251.1% against the industry’s 15% fall and the S&P 500 composite’s 34.5% growth.
The renowned animal health and mineral nutrition company has a market capitalization of $2.42 billion. PAHC has an earnings yield of 5.1% compared with the industry’s yield of 2.3%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 20.2%.
Let’s delve deeper.
Factors Favoring PAHC Stock
Robust Animal Health Growth: Within this, Phibro’s MFA portfolio was bolstered by the integration of Zoetis’ MFA business, which added more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China. In the second quarter of fiscal 2026, MFA revenues grew 34%, supported by strong gains in nutritional specialties and vaccines. The new MFA business contributed a full quarter of sales of $94.1 million compared with a partial quarter last year. Nutritional Specialty net sales increased 9% due to higher demand for dairy in North America.
Image Source: Zacks Investment Research
In October, the company signed a licensing agreement with Lighthouse Pharmaceuticals, Inc, gaining exclusive rights to develop, manufacture and commercialize the latter’s proprietary compound for canine periodontal care. Phibro also rolled out the Restoris piezoelectric dental gel nationwide, a product designed to treat and support long-term oral health in dogs with periodontal disease.
Vaccine Business Thrives: Phibro is focusing on new developments, along with incremental registrations and growing volumes of existing vaccine technologies. The company markets approximately 50 product lines for the prevention of diseases in poultry, including vaccines to protect against Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza. Phibro makes significant investments to expand vaccine manufacturing capacity at several locations, such as its vaccine production facility in Guarulhos, Brazil.
In the second quarter of fiscal 2026, net sales of vaccines increased 13% year over year, primarily driven by continued growth of poultry products in Latin America and higher international demand. Supported by expanding capacity and sustained global demand, the vaccines business is expected to emerge as a key growth driver in fiscal 2026.
Growth Potential in Emerging Markets: Phibro’s existing operations and established sales, marketing and distribution network in approximately 90 countries provide it ample scope to take advantage of global growth opportunities. Outside the United States, Phibro’s global footprint extends to key high-growth regions (countries where the livestock production growth rate is expected to be higher than the average growth rate), including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries, and South Africa and other countries in Africa. In the second quarter of fiscal 2026, net sales in Europe, the Middle East and Africa increased 37.4%, and Asia Pacific sales rallied 1.1%.
What Ails Phibro?
Macroeconomic Risks Loom: In the current scenario, Phibro’s business continues to be affected by economic sanctions, bans and broader military conflicts resulting from the ongoing armed conflict between Russia and Ukraine. Changes in the U.S. trade policy, including tariffs and revised trade agreements, could create supply-chain inefficiencies and affect the cost and availability of key materials. Other risks include macroeconomic instability from the exclusion of Russian financial institutions from the global banking system, inflationary pressures on raw materials and energy and heightened cybersecurity threats. All of these factors could reduce Phibro’s profitability and weigh on its overall financial performance.
Generic Pressure May Affect Growth: Phibro faces competition from lower-priced generic alternatives and new competitive products, limiting the protection afforded by its trade secrets. Generic competitors are becoming more aggressive in terms of pricing, and generic products form a considerable proportion of overall animal health sales in certain regions. If animal health customers increase their use of new or existing generic products, it will adversely affect Phibro’s financial health and operational performance.
PAHC Stock Estimate Trend
The Zacks Consensus Estimate for Phibro’s fiscal 2026 earnings per share (EPS) projects 45% growth to $3.03. The estimate has remained constant in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.48 billion. This suggests a 14.5% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , BrightSpring Health Services (BTSG - Free Report) and Cardinal Health (CAH - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s negative 2.2% yield. Its earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 33.4% compared with the industry’s 4.7% growth in the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health Services, sporting a Zacks Rank #1 at present, has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. Shares of the company have surged 173.9% compared with the industry’s 0.7% growth in the past year. BTSG’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 40.4%.
Cardinal Health, carrying a Zacks Rank #2 (Buy), has an earnings yield of 4.8% compared with the industry’s 6.5% yield. Shares of the company have rallied 60% compared with the industry’s 12.7% growth. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.